CLEC10A/CD301 Antibody (YA7116)

CLEC10A/CD301 Antibody (YA7116) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CLEC10A/CD301.

For research use only. We do not sell to patients.
  • Host:

    Mouse

  • Isotype:

    IgG1

  • Application:

    FC, ELISA

  • Reactivity :

    Human

  • Formulation:

    Supplied in PBS with 0.05% sodium azide

  • Conjugation:
    Non-conjugated

Applications

Application
FC Info
FC: Flow Cytometry
ELISA Info
ELISA: Enzyme Linked Immunosorbent Assay
Dilution Ratio 1:200-1:400 1:10000

Product Details

Description

CLEC10A/CD301 Antibody (YA7116) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CLEC10A/CD301.

  • Host Mouse
  • Clonality Monoclonal
  • Species Reactivity
    Human
  • Calculated Molecular Weight Predicted band size: 35.4kDa;
Species Reactivity Database
Immunogen

Purified recombinant fragment of human CD301 (AA: extra 158-316) expressed in E. Coli.

Sensitivity

Endogenous

Purification

affinity purified.

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG1

Product Properties

  • Appearance

    Liquid

  • Formulation

    Supplied in PBS with 0.05% sodium azide

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Background

  • Function

    CLEC10A/CD301 is a C-type lectin receptor involved in recognition of N-acetylgalactosamine (GalNAc)-terminated glycans by myeloid antigen presenting cells (APCs). Binds in a Ca(2+)-dependent manner to alpha- and beta-linked GalNAc residues on glycoprotein and glycolipid antigens, including alphaGalNAc- and Galbeta1->3GalNAc-O-Ser/Thr also known as Tn and T antigens, LacdiNAc epitope GalNAcbeta1->4GlcNAc and its derivative GalNAcbeta1->4-(Fucalpha1->3)GlcNAc, O-linked core 5 and 6 glycans, and GM2 and GD2 gangliosides. Acts as a signaling receptor at the interface of APC-T cell interactions. On immature dendritic cells, recognizes Tn antigen-carrying PTPRC/CD45 receptor on effector T cells and downregulates PTRPN/CD45 phosphatase activity with an impact on T cell activation threshold, cytokine production and proliferation. Modulates dendritic cell maturation toward a tolerogenic phenotype leading to generation of regulatory CD4-positive T cell subset with immune suppressive functions. Acts as an endocytic pattern recognition receptor involved in antitumor immunity. During tumorigenesis, recognizes Tn antigens and its sialylated forms Neu5Ac-Tn and Neu5Gc-Tn expressed on tumor cell mucins. On immature dendritic cells, can internalize Tn-terminated immunogens and target them to endolysosomal compartment for MHC class I and II antigen presentation to CD8-positive and CD4-positive T cells, respectively[1][2][3][4][5][6][7][8].

  • Subcellular Localization

    Cell membrane,Early endosome membrane,Lysosome membrane

  • Expression


    Tissue_Specificity: Expressed in myeloid antigen presenting cells in lymph nodes and skin (at protein level). Expressed in dermal dendritic cells (at protein level)

  • Isoforms & Post-Translational Modification

    Q8IUN9 has three isomers: Q8IUN9-1: 35446 Da (predicted); Q8IUN9-2: 32884 Da (predicted); Q8IUN9-3: 28877 Da (predicted).

  • Subunit

    Interacts with A-, B- and C-domain containing PTPRC/CD45 isoforms: isoform 1/CD45ABC, isoform 3/CD45AB, isoform 5/CD45BC and isoform 7/CD45B

  • SwissProt ID

    Q8IUN9

CLEC10A/CD301 Antibody (YA7116) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00